BioCentury
ARTICLE | Product Development

Exacerbation management

Why anti-inflammatories for cystic fibrosis need a new regulatory endpoint

August 11, 2018 12:00 AM UTC

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1.

The company is developing lenabasum, a synthetic cannabinoid receptor 2 (CB2; CNR2) agonist that acts as an anti-inflammatory agent. CB2 activation inhibits proinflammatory cytokine generation, suppresses leukocyte trafficking and stimulates synthesis of anti-inflammatory molecule lipoxin A4 (LXA4)...